Clinical trials: Second-Line
Refractory Metastatic Colorectal Cancer
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
For patients with metastatic colorectal cancer (mCRC) who have failed two or more lines of standard therapy, treatment options are extremely limited, and the prognosis remains poor, with objective response rates (ORRs) generally…
- Trial name
- NCT07896096
- Testing
- Ivarmacitinib Sulfate Tablets, Camrelizumab, Fruquintinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Renmin Hospital of Wuhan University
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
- Trial name
- NCT01611558
- Testing
- Ipilimumab
- Where
- 17 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus…
- Trial name
- NCT07244926
- Testing
- Sacituzumab tirumotecan plus bevacizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Neoplasms, Docetaxel
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Conditions
- Lung Neoplasms, Docetaxel, Pemetrexed, S-1
- Trial name
- NCT03589950
- Testing
- anlotinib plus chemotherapy, chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First People's Hospital of Lianyungang
HCC
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable…
- Trial name
- NCT07099274
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Phase II - Treatment Regimen Exploration Stage: 1. Evaluate the safety and efficacy of the following three treatment regimens: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV +…
- Conditions
- Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
- Trial name
- NCT07585279
- Testing
- Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Hebei Medical University Fourth Hospital
Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection
A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer
This study is a single-arm, open, phase II clinical trial aimed at evaluating the anti-tumor efficacy and safety of paclitaxel polymeric micelles for injection combined with furquintinib as second-line treatment for advanced…
- Conditions
- Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection, Fruquintinib Capsules
- Trial name
- NCT06706895
- Testing
- Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules
- Volunteers
- 21 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Breast Cancer
Second Line Breast Cancer Trial
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
- Trial name
- NCT00635713
- Testing
- Fulvestrant, Anastrozole
- Volunteers
- 588 people
- Sponsor
- AstraZeneca
Chronic Myelomonocytic Leukemia
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML.
- Trial name
- NCT06071624
- Testing
- CD4CAR
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Huda Salman
HIV/AIDS
"Switch Either Near Suppression Or THOusand"
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL.
- Trial name
- SESOTHO (NCT03088241)
- Testing
- switch
- Where
- 8 sites in Lesotho
- Volunteers
- 80 people
- Sponsor
- Niklaus Labhardt
Urothelial Carcinoma
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
- Trial name
- AVESEC (NCT07460245)
- Testing
- Avelumab 800 mg flat-dose IV
- Where
- 19 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Lung Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005972
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 50 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloid Leukemia
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder characterized by a translocation between chromosome 9 and 22, leading to a pathogenic tyrosine kinase signal transduction protein.
- Trial name
- NCT01805843
- Testing
- Echo, exercise echo, and if indicated, right heart catheter
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Medical University of Graz
NSCLC (Non-small Cell Lung Cancer)
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
- Trial name
- NCT07330050
- Testing
- Whole Agonist-Stimulated T (WAST) cells injection, Docetaxel
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma, Second-line Treatment
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival.
- Trial name
- NCT03251443
- Testing
- Apatinib
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00698815
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Where
- 129 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
Parasacral TENS Project
The purpose of the project is to compare the efficacy of parasacral transcutaneous electric nerve stimulation (TENS) versus standard second-line therapy (oral anticholinergics) for pediatric patients with overactive bladder (OAB)…
- Trial name
- NCT07892417
- Testing
- Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Small Cell Lung Cancer
Study of Picoplatin Efficacy After Relapse
Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options.
- Trial name
- SPEAR (NCT00465491)
- Testing
- picoplatin, best supportive care
- Where
- 143 sites in Argentina, Belarus and 13 more
- Volunteers
- 399 people
- Sponsor
- Poniard Pharmaceuticals
Advanced Melanoma, Cancer
Phase II Study of Tesetaxel in Metastatic Melanoma
The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.
- Trial name
- NCT01064713
- Testing
- Tesetaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Renal Cell Carcinoma (aRCC)
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination…
- Trial name
- CARINA (NCT04957160)
- Where
- 9 sites in United Kingdom
- Volunteers
- 281 people
- Sponsor
- Ipsen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.